Navigation Links
Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
Date:3/24/2008

hole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(TM) sports nutrition formula to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas that meet and succeed the nutritional requirements of the assisted living community.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties a
'/>"/>

SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Millennium Over-Delivers on 2007 Goals and Financial Guidance
2. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
3. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
4. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
5. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
6. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
7. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
8. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
9. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
10. Life Sciences Leader Joins Millennium Board of Directors
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Pharma Packaging ... position themselves for their 89th year in ... encoding, Pharma Packaging Solutions is preparing packaging ... software and new procedures. Establishing training and ... Practices (cGMP), Pharma Packaging Solutions will be ...
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive interim results ... evaluate once-weekly TransCon Growth Hormone in children with ... results will be presented at the 7th International ... held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... 16, 2014 BCC Research reveals ... STEM CELLS , the global market for stem cells ... 2018, with a five-year compound annual growth rate (CAGR) ... the Americas with growth projections of $2.2 billion in ... (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential applications ...
Breaking Biology Technology:Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3
... OF INDUSTRY, Calif. and HONG KONG, June 30 EFT BioTech ... has successfully completed its inaugural Taiwan Strait passenger voyage which has ... the Taiwan Sun, and the Qatar Tribune. The article states: ... with China on Sunday, making it the first such cross-strait service ...
... Mass., June 30 Microfluidics, a wholly owned ... MFLU), and Particle Sciences Inc. (PSI) have formed ... the most advanced and reliable nanotechnology and formulation ... Pharmaceutical Ingredients (APIs). , , Particle Sciences ...
... from the Taichung Harbor to Xiamen , China ... , , CITY OF INDUSTRY, Calif. and HONG ... announced today that the Company,s subsidiary, Excalibur International Marine Corporation, completed ... 2009. The voyage across the Taiwan Strait takes only 4 ...
Cached Biology Technology:Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 2Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 3Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 2EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 3
(Date:9/16/2014)... Johns Hopkins neuroscientists have discovered the "molecular brakes" that ... ear cochleas of mice. These "hair cells" translate sound ... brain and are interpreted as sounds. If the arrangement ... , A summary of the research will be published ... 16. , "The proteins Hey1 and Hey2 act as ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... Hesperides vessel returned to Spain culminating the around the ... clear picture of how the global ocean works and ... pollutants from the atmosphere is not limited to coastal ... of the planet, and it is already affecting the ... week in CSIC Residence for Researchers in Barcelona, in ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... is on the rise and may be problematic, according ... the December issue of Obstetrics & Gynecology, Erin Tracy, ... and may present potential pitfalls for patients and physicians. ... have no proven clinical validity whatsoever and are quite ...
... for advanced age-related macular degeneration, researchers from Harvard and ... the cure. A research report published in the December ... endostatin to mice significantly reduced or eliminated abnormal blood ... the disease causes blindness. Our study provides ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2New treatment for age-related macular degeneration within sight 2Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
Request Info...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... BUF040A is a diluent that is designed for ... which are paired with a mouse monoclonal coating ... rabbit and mouse proteins to prevent non-specific binding ... • This buffer may be used ...
Biology Products: